“Health Canada authorized Evusheld (tixagevimab and cilgavimab) for the prevention of COVID-19. After a thorough and independent scientific review of the evidence, the Department has determined that Evusheld meets Health Canada’s stringent safety, efficacy and quality requirements.
The drug is approved for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 and have not had recent known contact with someone infected with COVID-19, and:
- who are immune compromised and unlikely to mount an adequate immune response to COVID‐19 vaccination; or,
- for whom COVID-19 vaccination is not recommended.
Patients should talk to their healthcare provider to determine if Evusheld is appropriate for them. Evusheld is not currently authorized to treat COVID-19 infection, nor is it authorized to prevent infection in people who have been exposed to the virus.”
Health Canada authorizes Evusheld for the prevention of COVID-19 in immune compromised adults and children via Health Canada.
UBC Family Practice Residency Program: Abbotsford-Mission Site 